FDA Adverse Event Injury Summary report: N

LIFEWATCH MOBILE CARDIAC TELEMETRY MCT 3-LEAD ( UNIVERSAL GATEWAY)

MDR report key: 12696821 · Received October 26, 2021

Report

Report Number
3027765-2021-00011
Event Type
Injury
Date Received
October 26, 2021
Date of Event
October 7, 2021
Report Date
October 26, 2021
Manufacturer
LIFEWATCH SERVICES, INC.
Product Code
DSI
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IA, US
Reporter Occupation
003

Narratives

Additional Manufacturer Narrative · 1

PER PATIENT USER GUIDE SUP546, PATIENTS ARE PROVIDED WARNING STATEMENTS REGARDING ELECTRODE SKIN IRRITATION. PATIENTS ARE INSTRUCTED TO CONTACT LIFEWATCH SERVICES CUSTOMER SUPPORT PRIOR TO USING THE MCT 3L MONITORING SYSTEM IF THEY HAVE KNOWN ALLERGIES TO NICKEL OR OTHER METALS. THE PATIENT IS ALSO INFORMED IN THE USER GUIDE THAT IF THEY DEVELOP SKIN IRRITATION THEY SHOULD CONTACT THEIR HEALTHCARE PROFESSIONAL. THE PATIENT PRESENTED TO THEIR HEALTH CARE PROVIDER FOR PRESCRIPTIVE TREATMENT. THE HEALTH CARE PROVIDER IDENTIFIED THE SKIN IRRITATION. THE PATIENT STATED THEY HAD SKIN SENSITIVITY. PATIENT SELF-MEDICATED WITH NEOSPORING. PATIENT WAS PRESCRIBED FLUOCINOLONEACETONIDE TO CLEAR UP THE AFFECTED AREA. THE IFU LOCATED ON THE POUCH STATES THE ELECTRODES ARE HYPOALLERGENIC AND AN ELECTRODE IS TO BE WORN FOR LESS THAN 72 HOURS. THE ELECTRODES ARE ALSO PVC AND LATEX FREE. THE ELECTRODE SUPPLIER HAS NOT UNDERGONE CHANGES IN THE PRODUCTION PROCESS OR RAW MATERIALS AND MEET REQUIREMENTS FOR SKIN SENSITIVITY / CYTOTOXICITY / IRRITATION. NO ADDITIONAL INFORMATION IS KNOWN TO LIFEWATCH SERVICES, INC. AT THIS TIME.

Description of Event or Problem · 1

PATIENT COMMUNICATION OF CONSULTING A HEALTHCARE PROFESSIONAL DUE TO ALLERGIC REACTION/SKIN IRRITATION WHERE TREATMENT WAS PRESCRIBED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1593327 LIFEWATCH MOBILE CARDIAC TELEMETRY MCT 3-LEAD ( UNIVERSAL GATEWAY) PLATINUM SENSOR DSI LIFEWATCH SERVICES, INC. MCT 3L ELECTRODE LOT 108134X

Patients

Seq Age Sex Outcome Treatment
1 36 YR Other